invex wanted a face to face meeting and the FDA neurology have promised written response only. the significance unclear, but generally interpreted as another setback.
the FDA ophthalmology sank Invex’s hopes of 1 trial with an ophthalmology endpoint, so the market is guessing that Invex won’t have much luck with getting 1 trial with the fda neurology.
and as we’ve seen with the ASX. They prefer the FDA rather than the EMA, seeing it as traditionally the largest market despite Invex insisting that there’s a larger population to treat in the EU.
- Forums
- ASX - By Stock
- Ann: Invex Granted Type C Meeting with FDA
invex wanted a face to face meeting and the FDA neurology have...
-
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
7.6¢ |
Change
0.002(2.70%) |
Mkt cap ! $5.561M |
Open | High | Low | Value | Volume |
7.0¢ | 7.6¢ | 7.0¢ | $9.48K | 128.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 31159 | 7.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.6¢ | 14470 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31159 | 0.071 |
1 | 100000 | 0.070 |
1 | 10000 | 0.051 |
1 | 200000 | 0.050 |
1 | 60001 | 0.043 |
Price($) | Vol. | No. |
---|---|---|
0.076 | 14470 | 2 |
0.077 | 7950 | 1 |
0.078 | 20000 | 1 |
0.080 | 10000 | 1 |
0.081 | 888 | 1 |
Last trade - 10.51am 24/06/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online